RhoVac AB announces that the first patient in the company’s clinical phase I/II study has now completed the treatment phase with cancer vaccine RV001
In April 2017, RhoVac AB ("RhoVac") announced that the treatment of the first patient in phase I/II clinical study was initiated. The company now announces that the same patient has completed the treatment phase on eleven doses of cancer vaccine RV001. RhoVac's CEO Anders Ljungqvist has provided more information about the status of the clinical study in this newsletter.
On April 5th 2017, RhoVac announced that the first patient in phase I/II clinical study was treated with company's cancer vaccine, RV001. At the beginning of July 2017, it was announced that the patient recruitment for this study was completed and all 22 patients were in the treatment phase. Currently, mid-November 2017, an update on the status of the study is that all recruited patients have been treated with at least eight of a total of eleven doses. The first patient has completed the treatment phase and has received a total of eleven doses of RV001. This patient will now continue in the follow-up phase of the clinical study. The treatment phase for patient number two is expected to be completed at the end of November, and the final patient is expected to complete the treatment phase, as previously planned, in February 2018. After this, the immunological analysis will follow, and reporting of the study is estimated to take place in the second quarter of 2018.
RhoVac’s clinical phase I/II study comprises a total of 22 patients with diagnosed prostate cancer in control phase. The study is an open study, which means that both the patient and the treating physician know what the patient is treated with. The primary objective of the open study is to evaluate the safety of RV001 vaccination therapy and the secondary objective is to evaluate immunological response in treatment with the RhoVac’s cancer vaccine. One patient has chosen to discontinue his participation in this study for personal reasons, which is not uncommon in clinical trials with relatively long treatment periods. The absence of one patient will not affect clinical trial’s time schedule and RhoVac is still experiencing a considerable commitment from the patients in the study. RhoVac has not encountered any safety issues that hinder the continuation of the study and the intention is thus to complete the clinical phase I/II study according to the schedule.
The ongoing study provides the basis for the continuation of the clinical development of RhoVac's cancer vaccine RV001, a targeted therapy aiming at controlling or limiting cancer metastasis. It is of crucial importance that the company has a well-documented clinical development plan to present to international pharmaceutical companies and potential investors in order to increase interest in the project.
For more information, please contact:
Anders Ljungqvist – CEO, RhoVac AB
Phone: +45 4083 2365
About RhoVac AB
RhoVac AB conducts research and development of immunotherapeutic drugs. The company's main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac's first drug candidate has completed pre-clinical phase and clinical phase I / II study has started spring 2017. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on AktieTorget, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com